Skip to content
Screener

Kodiak Sciences Inc KOD Financing Cash Flow

Financing Cash Flow at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
-$1.22B-8.5%
EyePoint, Inc. logo
EyePoint, Inc.EYPT
$19.99M+8,300%
KLR
Kalaris TherapeuticsKLRS
-$1.7M-102%
4D Molecular Therapeutics logo
4D Molecular TherapeuticsFDMT
$11.48M
HRO
HarrowHROW
$48.91M+212,561%
PVL
Palvella TherapeuticsPVLA
$214.73M+17,964%

Other financials

Income statement

See full
Operating income-$59.8M-1.2%
Net income-$58.2M-1.2%
EPS (diluted)-$0.94+13.8%

Balance sheet

See full
Cash & equivalents$169.5M+22.1%
Total debt$56.0M-17.2%
Total equity$112.1M+3.0%
Total assets$306.0M+2.7%

Cash flow

See full
Operating cash flow-$40.0M-37.6%
CapEx$942.0K+249%
Free cash flow-$41.0M-39.5%

Valuation

See full
Market cap$2.84B+556%
Enterprise value$2.73B+592%

Returns & leverage

See full
Return on equity-208.8%+2,306pp
Debt / equity0.5×-0.1×
Current ratio3.5×-1.1×

Where this comes from

Reported directly by Kodiak Sciences Inc in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The source filing: Kodiak Sciences Inc’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 4:15 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-211951
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Cash flows from financing activities
Payment of public offering costs(303)
Proceeds from stock option exercises922124
Net cash provided by financing activities619124
Net decrease in cash, cash equivalents and restricted cash(40,332)(29,223)
Cash, cash equivalents and restricted cash, at beginning of period216,046174,258
Cash, cash equivalents and restricted cash, at end of period$175,714$145,035
Reconciliation of cash, cash equivalents and restricted cash to consolidated balance sheets:

Item 1. Financial Statements (Unaudited).

FAQ

What is Kodiak Sciences Inc's financing cash flow?
Kodiak Sciences Inc (KOD) reported financing cash flow of $619K in Q1 2026.
How has Kodiak Sciences Inc's financing cash flow changed year-over-year?
Kodiak Sciences Inc's financing cash flow increased by 399.2% year-over-year, from $124K to $619K.
What is the long-term trend for Kodiak Sciences Inc's financing cash flow?
Over 3 years (2021 to 2025), Kodiak Sciences Inc's financing cash flow has grown at a 179.3% compound annual growth rate (CAGR), from $8.18M to $178.3M.
What does financing cash flow mean?
Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.

Ask your AI about Kodiak Sciences Inc's financing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude